We investigated the effect of treatment with biofeedback-associated progressive muscle relaxation on 10 patients with poorly controlled type I diabetes mellitus compared with 10 equivalent untreated patients. In contrast to previous studies of patients with type II diabetes, no improvement occurred in glucose tolerance after 1 wk of intensive in-hospital relaxation training or in glycohemoglobin and total daily insulin dose after 6 wk of practicing relaxation techniques at home. This and other studies suggest that this type and amount relaxation therapy may not be as useful for enhancing blood glucose control in patients with type I diabetes as in those with type II diabetes. However, subpopulations of type I diabetic patients who have demonstrated stress-induced hyperglycemia should be further investigated.
CGM data can be summarized and reviewed retrospectively. CLARITY provides options for reviewing data from Dexcom CGM systems, including on-demand reports and five types of notifications (disabled by default) that are auto-generated and pushed to users’ smart devices. We examined user engagement with CLARITY reports and notifications, and their associations with estimated glucose value (EGV)-based parameters. EGVs uploaded in October 2019 from a convenience sample of 2,637 U.S.-based users of Dexcom CGM systems were analyzed. Group 1 did not access CLARITY, Group 2 accessed on-demand reports but not auto-generated notifications, and Group 3 enabled all types of auto-generated notifications throughout that month. For each group, EGV-based parameters including time in range (TIR) and the % of users meeting consensus-based goals were calculated. Unpaired t-tests were used to compare time in ranges; two-proportion z-tests were used to compare % of users meeting goals. Auto-generated CLARITY notifications were associated with more TIR and less time spent in hyperglycemia, with clinically and statistically significant differences in favor of Group 3 vs. Group 1. A significantly higher proportion of users in Group 3 than in Group 1 met consensus goals for TIR (Table). Push notifications related to CGM data may contribute to patient engagement and/or to beneficial therapeutic choices. Disclosure K. Shankar: Employee; Self; Dexcom, Inc. P. Hastedt: None. M. Derdzinski: Employee; Self; Dexcom, Inc. J. Welsh: Employee; Self; CSL Behring. C. Barger: Employee; Self; Dexcom, Inc. G. Cohen: Employee; Self; Dexcom, Inc.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.